健择联合顺铂化疗对非小细胞肺癌患者外周血CD4^+CD25^+Foxp3^+调节T细胞的影响  

Changes of the CD4^+CD25^+Foxp3^+ Treg Cells in Peripheral Blood in Patients with NSCLC with Gemzar and Cisplatin Regimen

作　　者：周娓 喻杰[2] 刘莉[2] 刘仲萍[3] 

机构地区：[1]湖北省鄂州市中医院肿瘤科,436000 [2]华中科技大学附属协和医院肿瘤诊疗研究中心 [3]华中科技大学附属协和医院干细胞中心

出　　处：《肿瘤防治研究》2008年第5期343-346,共4页Cancer Research on Prevention and Treatment

摘　　要：目的探讨健择联合顺铂对非小细胞肺癌患者免疫耐受的调控作用。方法38例经病理学或细胞学确诊的NSCLC患者,采用健择、顺铂联合化疗方案,应用流式细胞仪检测化疗前后外周血CD4+CD25+Foxp3+调节T细胞(Treg)占CD4+T细胞的百分率。结果化疗前NSCLC患者外周血CD4+CD25+Foxp3+调节T细胞(Treg)占CD4+T细胞的比率明显高于健康对照组(P<0.05);化疗后NSCLC患者外周血CD4+CD25+Foxp3+调节T细胞(Treg)占CD4+T细胞的百分率较化疗前显著降低(P<0.05);但鳞癌、腺癌及腺鳞癌3组间化疗前、化疗后各项指标之间差异无统计学意义(P>0.05)。结论健择联合顺铂化疗可调控晚期非小细胞肺癌机体的肿瘤免疫耐受,改善患者的免疫功能。Objective To investgate the effect on immune function of patients with non-small cell lung cancer （NSCLC） treated with gemcitabine and cisplatin regimen. Methods The prevalence of CD4^＋ CD25^＋ Foxp3^＋ T regulatory（Treg） cells in peripheral blood in 38 patients with NSCLC , treated with gemcitabine plus cisplatin chemotherapy regimen, was detected by flow cytometry. Results The percentage of CD4^＋ CD25^＋ Foxp3 ^＋ Treg cells in peripheral blood of the patients with NSCLC pre-chemotherapy was significantly higher than that in healthy doners; compared with pre-chemotherapy , the percentage of CD4^＋ CD25 ^＋ Foxp3 ^＋ Treg cells in peripheral blood was significantly decreased in post-chemotherapy pa tients （P〈0. 05） ; there were no significant differences observed among squamous cell carcinoma, adenocarcinoma and adenosquamocarcinoma （P〉0.05）. Conclusion Gemcitabine plus cisplatin chemotherapy can improve the immune-tolerance in advanced non-small cell lung cancer patients.

关 键 词：CD4^+CD25^+FOXP3^+ 调节T细胞(Treg) 流式细胞术 化疗 

分 类 号：R730.53[医药卫生—肿瘤]